TransMedics Group (NASDAQ:TMDX) Receives Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of TransMedics Group (NASDAQ:TMDX) in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $104.00 price objective on the stock.

Other equities research analysts have also issued research reports about the stock. TD Cowen cut their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Robert W. Baird cut their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Oppenheimer restated an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a report on Tuesday, December 3rd. Finally, Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Up 2.5 %

TMDX stock opened at $67.65 on Tuesday. TransMedics Group has a 52-week low of $55.00 and a 52-week high of $177.37. The company’s 50 day simple moving average is $68.55 and its 200-day simple moving average is $95.67. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm has a market capitalization of $2.28 billion, a P/E ratio of 71.97 and a beta of 2.12.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Braidwell LP acquired a new position in shares of TransMedics Group during the 4th quarter worth $57,493,000. Norges Bank acquired a new position in shares of TransMedics Group during the 4th quarter worth $22,861,000. Mackenzie Financial Corp increased its stake in shares of TransMedics Group by 73.0% during the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock worth $51,635,000 after purchasing an additional 349,403 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of TransMedics Group by 1,565.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company’s stock worth $16,820,000 after purchasing an additional 253,624 shares during the last quarter. Finally, Emerald Advisers LLC increased its stake in shares of TransMedics Group by 146.3% during the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock worth $23,176,000 after purchasing an additional 220,804 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.